dabrafenib
Showing 26 - 50 of 78
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation Trial in Villejuif (Trametinib,
Active, not recruiting
- Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
- Trametinib
- +3 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Sep 27, 2021
Malignant Melanoma Trial in Herlev, Aarhus, Odense (Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab
Recruiting
- Malignant Melanoma
- Pembrolizumab Injection [Keytruda]
- +6 more
-
Herlev, Hovedstaden, Denmark
- +2 more
Sep 16, 2022
Melanoma, Brain Metastases Trial in Canada (Dabrafenib, Trametinib)
Terminated
- Melanoma
- Brain Metastases
- Dabrafenib
- Trametinib
-
Halifax, Nova Scotia, Canada
- +5 more
Aug 18, 2021
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)
Terminated
- BRAF V600E Mutation Present
- +7 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Mar 9, 2022
Melanoma Trial in Jette (Dabrafenib, Trametinib, Hydroxychloroquine)
Recruiting
- Melanoma
- Dabrafenib
- +2 more
-
Jette, Brabant, BelgiumUZ Brussel
Apr 27, 2021
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma Trial in Worldwide (dabrafenib, trametinib)
Recruiting
- Diffuse Astrocytoma
- +22 more
- dabrafenib
- trametinib
-
Phoenix, Arizona
- +26 more
Jan 27, 2023
Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)
Recruiting
- Rare Tumor
- Refractory Tumor
- Gefitinib
- +11 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Feb 16, 2022
Thyroid Gland Anaplastic Carcinoma Trial in Saint Petersburg (Dabrafenib, Trametinib)
Recruiting
- Thyroid Gland Anaplastic Carcinoma
- Dabrafenib
- Trametinib
-
Saint Petersburg, Russian FederationSaint-Petersburg State University (SPSU) N.I.Pirogov Clinic of H
Feb 3, 2021
Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)
Active, not recruiting
- Melanoma
- Dabrafenib
- +2 more
-
Boston, Massachusetts
- +2 more
Jun 14, 2022
Targeted Therapies in BRAF Positive Metastatic Melanoma in US
Active, not recruiting
- Melanoma
- Encorafenib
- +5 more
-
New York, New YorkPfizer Investigational Site
Feb 18, 2022
Stage IV Melanoma, Stage III Melanoma Trial in Jette (Trametinib, Dabrafenib)
Recruiting
- Stage IV Melanoma
- Stage III Melanoma
- Trametinib
- Dabrafenib
-
Jette, Brussels, BelgiumUniversitair Ziekenhuis Brussel
Sep 29, 2021
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023
Renal Impairment Trial in DeBary, Berlin, Raleigh (dabrafenib)
Completed
- Renal Impairment
- dabrafenib
-
DeBary, Florida
- +2 more
Dec 6, 2020
Hepatic Impairment Trial in United States (dabrafenib)
Terminated
- Hepatic Impairment
- dabrafenib
-
Los Angeles, California
- +3 more
Dec 6, 2020
Advanced Malignancy, Advanced Solid Tumors, Cancer Trial in Australia, United States (AMG 232, Trametinib, Dabrafenib)
Completed
- Advanced Malignancy
- +6 more
- AMG 232
- +2 more
-
Los Angeles, California
- +6 more
Mar 24, 2021
Melanoma Trial in Cambridge (Dabrafenib, Trametinib)
Completed
- Melanoma
- Dabrafenib
- Trametinib
-
Cambridge, England, United KingdomAddenbrooke's Hospital
Dec 4, 2020
Melanoma, BRAF Gene Mutation Trial in Germantown (Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene
Unknown status
- Melanoma
- BRAF Gene Mutation
- Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
- +3 more
-
Germantown, TennesseeWest Cancer Center
Oct 9, 2020
Melanoma Trial in New York (Dabrafenib)
Completed
- Melanoma
- Dabrafenib
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 8, 2020